Solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related thereto

US10059660B2 · kind B2 · utility

Assignee

• Millendo Therapeutics, Inc · US

Inventors

• Stephen Warren Hunt, III · Dexter, US
• Martin Douglas Phillips · Bryn Mawr, US
• Robert Matunas · Plainsboro, US
• Herman Chen · Madison, US
• Aimesther Betancourt · Montréal, CA
• Charles Uzarama · Laval, CA
• Roch Thibert · Mount Royal, CA

Key dates

• Filing date: Dec 6, 2016
• Grant date: Aug 28, 2018
• Expiry date: Dec 6, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2601/08
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.